Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

rm using the effective interest method.

The foreign exchange gains and losses were nominal for each of Q1/08 and Q1/07.

Liquidity and Capital Resources

As of July 31, 2007, the Company had cash, cash equivalents and short-term investments of $12.8 million (April 30, 2007: $15.3 million) and the Company's net working capital was $12.1 million (April 30, 2007: $14.6 million). The $2.5 million decrease in net working capital from April 30, 2007 is primarily attributable to the cash loss of $2.4 million (loss excluding non-cash expenses: amortization, stock-based compensation and accretion of the convertible royalty participation units) for the three months ended July 31, 2007.

MIGENIX believes that its funds on hand at July 31, 2007, together with ongoing cost containment measures and expected interest income, are sufficient to provide for operations into the third quarter of calendar 2008 before funds received, if any, from existing or new license agreements, the exercise of warrants and options and future financing activities. The Company will continue advancing its highest priority programs while operating within an annual burn rate of $11 million to $13 million. The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the programs, and we may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained

Outstanding Shares

There are currently 94,463,806 (July 31, 2007: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (July 31, 2007 and April 30, 2007: 29,465); and 9,250,000 (July 31, 2007: 9,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. In May 2007 the Company converted 50,000 Series A and 50,000 Series B
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Z. Yang, Varian, Inc. , ... Bisphenol A (BPA) is a primary raw material used for the ... (4-NP) is a degradation product of alkylphenol ethoxylate detergents used in ... as an additive in plastics that are used for food packaging ...
... Jeffrey J. , Comerford#, Ph.D , ... Monash University, , Clayton campus, , ... Varian Australia, , 679 ... Victoria 3170, Australia , E-mail: fluorescence@varianinc.com , ...
... Purpose , Normal ... using the API 3000 LC/MS/MS System. , ... In recent years, pharmaceutical companies have placed greater importance ... Isomerspecific pharmaceuticals often exhibit increased potency, higher bioavailability and reduced side ...
Cached Biology Technology:Analysis of Phenolic Estrogen Mimics in River Water by Negative Ion Electrospray LC/MS/MS 2Minimizing Photobleaching of Blue Fluorescent Protein (BFP) using , the Varian Cary Eclipse Fluorescence Spectrophotometer 2Minimizing Photobleaching of Blue Fluorescent Protein (BFP) using , the Varian Cary Eclipse Fluorescence Spectrophotometer 3Minimizing Photobleaching of Blue Fluorescent Protein (BFP) using , the Varian Cary Eclipse Fluorescence Spectrophotometer 4Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System 2Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System 3
(Date:4/16/2014)... of yellow-shouldered bats have been unearthed by scientists at the ... Natural History and described in the open access journal ... genus Sturnira are part of a recent discovery ... the third one still waiting to be officially announced. , ... to contain only 14 species. In the last years closer ...
(Date:4/16/2014)... disease, spinal and bulbar muscular atrophy (SBMA) is a ... weakness and atrophy. Researchers have long considered it to ... the cells in the spinal cord and brainstem that ... published in the April 16, 2014 online issue of ... University of California, San Diego School of Medicine say ...
(Date:4/16/2014)... ability to store memories improves during childhood, associated ... connections with prefrontal and parietal cortices. New research ... regions develop at this crucial time. Eventually, that ... in the transition into and during adolescence and ... Located deep in the middle of the brain, ...
Breaking Biology News(10 mins):Two new species of yellow-shouldered bats endemic to the Neotropics 2Mutant protein in muscle linked to neuromuscular disorder 2How kids' brain structures grow as memory develops 2
... international team of scientists has released data indicating that ... thought because of methane emissions from freshwater areas. ... ecology, evolution and organismal biology department, is part of ... inland waters is higher than previous estimates. ...
... team took a significant step forward in understanding ... pollutants and some other gases, except carbon dioxide. ... with some studies suggesting the self-cleaning power of ... changes, while others suggest greater stability. And what ...
... 2011 Acceleron Pharma, Inc., a biopharmaceutical company developing ... tissues including muscle, bone, fat, red blood cells and ... $1.5 million grant from the Muscular Dystrophy Association to ... (DMD), a disabling neuromuscular disease in which patients experience ...
Cached Biology News:Freshwater methane release changes greenhouse gas equation 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: